The company Verovaccines, which is supported by the GO-Bio funding measure of the Federal Ministry of Education and Research, is developing novel animal vaccines using a proprietary technology platform based on the milk yeast Kluyveromyces lactis. These vaccines can be used against a variety of pathogens in different animal species.

With the two technology platforms Unified Vaccine Platform and Unified Manufacturing Platform, Verovaccines has now created all the technological prerequisites to enter a new phase of the company's development.

The Unified Vaccine Platform is used to design, test and develop K. lactis-based vaccines from recombinant design to registration. It integrates most development steps as interchangeable modules between different vaccines. This generates development synergies between vaccines and thus considerable time and cost savings in development.

The Unified Manufacturing Platform bundles technologies that allow fast, stable and 10 to 20 times more cost-effective production of K. lactis-based vaccines compared to reference technologies. A special feature is the "same-for-all" functionality, which enables the production of, for example, poultry and bovine vaccines with almost identical processes, equipment and materials.

Managing Director Dr Hanjo Hennemann: "We have recently completed a series of extensive validation and risk mitigation studies for both platforms. This means we can now focus on developing vaccines to bring them to market quickly. The upscaling studies have progressed to the point where we can reproducibly manufacture our most advanced development candidate on an industrial scale in a GMP facility."

Prof. Dr Sven-Erik Behrens, CSO, added: "We have initiated this growth phase by bringing another programme into the pipeline to develop a second proprietary porcine vaccine. This programme has already reached the prototype stage of the vaccine with several candidates."

About Verovaccines GmbH

Verovaccines GmbH is a spin-off of Prof. Dr Sven-Erik Behrens, Dr Hanjo Hennemann and Dr Martina Behrens from Martin Luther University Halle-Wittenberg. The spin-off company was founded in July 2017.